MA50096A - Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux - Google Patents
Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non virauxInfo
- Publication number
- MA50096A MA50096A MA050096A MA50096A MA50096A MA 50096 A MA50096 A MA 50096A MA 050096 A MA050096 A MA 050096A MA 50096 A MA50096 A MA 50096A MA 50096 A MA50096 A MA 50096A
- Authority
- MA
- Morocco
- Prior art keywords
- free dna
- lipid nanoparticle
- dna vectors
- nanoparticle formulations
- viral capside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556334P | 2017-09-08 | 2017-09-08 | |
| US201762556333P | 2017-09-08 | 2017-09-08 | |
| US201762556381P | 2017-09-09 | 2017-09-09 | |
| US201862675322P | 2018-05-23 | 2018-05-23 | |
| US201862675317P | 2018-05-23 | 2018-05-23 | |
| US201862675324P | 2018-05-23 | 2018-05-23 | |
| US201862675327P | 2018-05-23 | 2018-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50096A true MA50096A (fr) | 2020-07-15 |
Family
ID=65635269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050096A MA50096A (fr) | 2017-09-08 | 2018-09-07 | Formulations de nanoparticules lipidiques de vecteurs d'adn exempts de capside non viraux |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210059953A1 (fr) |
| EP (1) | EP3679148A4 (fr) |
| JP (3) | JP2020537493A (fr) |
| KR (1) | KR102696307B1 (fr) |
| CN (1) | CN111295448A (fr) |
| AU (1) | AU2018330208B2 (fr) |
| BR (1) | BR112020004219A2 (fr) |
| CA (1) | CA3075180A1 (fr) |
| CO (1) | CO2020002262A2 (fr) |
| IL (1) | IL272799B2 (fr) |
| MA (1) | MA50096A (fr) |
| MX (1) | MX2020002501A (fr) |
| MY (1) | MY209906A (fr) |
| PH (1) | PH12020500466A1 (fr) |
| SG (1) | SG11202000765PA (fr) |
| WO (1) | WO2019051289A1 (fr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020002394A2 (pt) | 2017-08-09 | 2020-07-28 | Bioverativ Therapeutics Inc. | moléculas de ácidos nucleicos e usos das mesmas |
| MA51842A (fr) * | 2018-02-14 | 2020-12-23 | Generation Bio Co | Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion |
| US20210346306A1 (en) * | 2018-05-23 | 2021-11-11 | Modernatx, Inc. | Delivery of dna |
| KR102925832B1 (ko) | 2018-08-09 | 2026-02-11 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도 |
| CA3147875A1 (fr) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Compositions a recombinase et leurs methodes d'utilisation |
| AU2020327960A1 (en) * | 2019-08-12 | 2022-02-17 | Generation Bio Co. | Methods and compositions for reducing gene or nucleic acid therapy-related immune responses |
| AU2020342668B2 (en) * | 2019-09-06 | 2025-10-09 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended DNA and cleavable lipids and methods of use thereof |
| US20220370357A1 (en) * | 2019-11-22 | 2022-11-24 | Generation Bio Co. | Ionizable lipids and nanoparticle compositions thereof |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| TW202206097A (zh) | 2020-05-20 | 2022-02-16 | 美商旗艦先鋒創新有限責任公司 | 冠狀病毒抗原組成物及其用途 |
| EP4153223A1 (fr) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Compositions immunogènes et leurs utilisations |
| IL298539A (en) | 2020-05-29 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Trem compositions and methods relating thereto |
| CA3182026A1 (fr) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Compositions a base de trem et procedes associes |
| EP4181948A4 (fr) * | 2020-07-17 | 2024-12-04 | Generation Bio Co. | Procédés d'encapsulation de polynucléotides dans nanoparticules lipidiques de taille réduite et nouvelle formulation associée |
| WO2022023284A1 (fr) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions de molécules d'adn, leurs procédés de fabrication et leurs procédés d'utilisation |
| EP4208196A1 (fr) | 2020-09-03 | 2023-07-12 | Flagship Pioneering Innovations VI, LLC | Compositions immunogènes et leurs utilisations |
| GB202014751D0 (en) | 2020-09-18 | 2020-11-04 | Lightbio Ltd | Targeting vector |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CA3200234A1 (fr) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Nanoparticules lipidiques utilisees pour l'administration d'acides nucleiques, et methodes d'utilisation associees |
| BR112023012377A2 (pt) | 2020-12-23 | 2023-10-24 | Flagship Pioneering Innovations Vi Llc | Composições de trems modificadas e usos das mesmas |
| WO2022155195A1 (fr) * | 2021-01-12 | 2022-07-21 | Peranteau William | Nanoparticules de lipide ionisables destinées à l'administration in utéro d'arnm |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240261395A1 (en) * | 2021-05-07 | 2024-08-08 | Generation Bio Co. | Lyophilized non-viral dna vector compositions and uses thereof |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4377457A1 (fr) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Compositions de trem et leurs utilisations |
| EP4124348A1 (fr) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticules pour l'administration de cellules |
| CN116179605B (zh) * | 2021-08-12 | 2025-11-11 | 蓝图生物医药(广州)有限公司 | 一种重组腺相关病毒载体及其应用 |
| DK4271818T3 (da) | 2021-09-17 | 2024-11-04 | Flagship Pioneering Innovations Vi Llc | Sammensætninger og fremgangsmåder til fremstilling af cirkulære polyribonukleotider |
| US20240417714A1 (en) | 2021-10-18 | 2024-12-19 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| CN118900845A (zh) | 2021-11-24 | 2024-11-05 | 旗舰创业创新六公司 | 冠状病毒免疫原组合物及其用途 |
| CA3238370A1 (fr) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Compositions d'immunogenes du virus varicelle-zona et leurs utilisations |
| IL312965A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| MX2024007307A (es) | 2021-12-17 | 2024-08-06 | Flagship Pioneering Innovations Vi Llc | Métodos de enriquecimiento de arn circular en condiciones desnaturalizantes. |
| AU2022417517A1 (en) | 2021-12-22 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| MX2024007870A (es) | 2021-12-23 | 2024-08-15 | Flagship Pioneering Innovations Vi Llc | Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos. |
| US20250134825A1 (en) * | 2022-02-02 | 2025-05-01 | Mslsolutions Gmbh | Method for producing medications and vaccines |
| AU2023235112A1 (en) * | 2022-03-14 | 2024-10-17 | Generation Bio Co. | Heterologous prime boost vaccine compositions and methods of use |
| EP4499607A1 (fr) | 2022-03-25 | 2025-02-05 | Sail Biomedicines, Inc. | Nouveaux lipides et nanoparticules lipidiques ionisables et leurs procédés d'utilisation |
| US20250228928A1 (en) * | 2022-04-04 | 2025-07-17 | Spark Therapeutics, Inc. | Immune enhancement and infectious disease treatment |
| WO2023196634A2 (fr) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccins et procédés associés |
| US20250295687A1 (en) | 2022-05-09 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| TW202409283A (zh) | 2022-05-13 | 2024-03-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 雙股ｄｎａ組合物及相關方法 |
| EP4531819A2 (fr) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Nanoparticules lipidiques pour l'administration d'acides nucléiques et leurs procédés d'utilisation |
| WO2023250112A1 (fr) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions de trem modifiées et leurs utilisations |
| WO2024015428A1 (fr) * | 2022-07-12 | 2024-01-18 | Trustees Of Boston University | Voies de signalisation cellulaire synthétiques et leurs utilisations |
| AU2023320333A1 (en) | 2022-08-01 | 2025-01-16 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| KR102544632B1 (ko) * | 2022-08-05 | 2023-06-16 | 주식회사 무진메디 | 장쇄 세라마이드가 포함된 지질 나노입자 및 이를 포함하는 세포 사멸용 조성물 |
| WO2024035952A1 (fr) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Procédés et compositions pour moduler l'épissage au niveau de sites d'épissage alternatifs |
| EP4581012A2 (fr) | 2022-08-31 | 2025-07-09 | Sail Biomedicines, Inc. | Nouveaux lipides ionisables et nanoparticules lipidiques, ainsi que procédés d'utilisation associés |
| WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
| EP4612296A1 (fr) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions et procédés de purification de polyribonucléotides |
| TW202434728A (zh) | 2022-11-08 | 2024-09-01 | 美商旗艦先鋒創新有限責任公司 | 用於產生環狀多核糖核苷酸的組成物和方法 |
| WO2024129988A1 (fr) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions et procédés d'administration d'agents thérapeutiques à un os |
| WO2024151673A2 (fr) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation de plaies |
| TW202438673A (zh) | 2023-01-09 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 疫苗及相關方法 |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024151685A1 (fr) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Molécules d'acide nucléique recombinant et leur utilisation dans la cicatrisation des plaies |
| WO2024167885A1 (fr) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Compositions immunomodulatrices et procédés associés |
| EP4665736A2 (fr) | 2023-02-13 | 2025-12-24 | Flagship Pioneering Innovations VII, LLC | Lipides ionisables contenant un lieur clivable et supports lipidiques pour compositions thérapeutiques |
| AU2024222598A1 (en) | 2023-02-17 | 2025-07-31 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
| JP2026507514A (ja) | 2023-02-17 | 2026-03-04 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | 修飾されたシトシンを含むｄｎａ組成物 |
| AU2024229184A1 (en) | 2023-03-02 | 2025-08-28 | Krystal Biotech, Inc. | Interleukin-2 and interleukin-12 for cancer therapy |
| WO2024192422A1 (fr) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Compositions immunogènes et leurs utilisations |
| AU2024235803A1 (en) | 2023-03-15 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| KR102938591B1 (ko) * | 2023-04-06 | 2026-03-12 | 주식회사 무진메디 | 수분산성이 우수한 고함량 세라마이드 조성물 |
| JP2026514004A (ja) | 2023-04-12 | 2026-05-01 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 修飾されたｔｒｅｍ、組成物及びその関連方法 |
| EP4695391A1 (fr) | 2023-04-12 | 2026-02-18 | Flagship Pioneering Innovations VI, LLC | Trems destinés à être utilisés dans la correction de mutations faux-sens |
| WO2024220746A2 (fr) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Agents d'arni ciblant la synthase d'acides gras et procédés associés |
| WO2024258829A1 (fr) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Compositions de vaccin contre le sars-cov-2 et procédés associés |
| WO2025006684A1 (fr) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Polyribonucléotides circulaires codant pour des polypeptides antifusogènes |
| US20250092426A1 (en) | 2023-07-25 | 2025-03-20 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025042786A1 (fr) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprenant des polyribonucléotides circulaires et leurs utilisations |
| WO2025049632A1 (fr) * | 2023-08-29 | 2025-03-06 | Rejuvenation Technologies Inc. | Compositions et méthodes pour l'administration large d'arn dans un tissu |
| WO2025054236A2 (fr) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Compositions de vaccin contre le sars-cov-2 et procédés associés |
| WO2025052180A2 (fr) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipides et nanoparticules lipidiques |
| TW202525266A (zh) | 2023-09-18 | 2025-07-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 可電離類脂質組成物及其治療用途 |
| WO2025072331A1 (fr) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Nucléases cas et procédés ou méthodes associés |
| WO2025096807A2 (fr) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Nouvelles formes d'adn thérapeutique |
| WO2025106670A1 (fr) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Compositions lipidoïdes ionisables et leurs utilisations thérapeutiques |
| TW202523695A (zh) | 2023-11-22 | 2025-06-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於治療非酒精性脂肪性肝病之方法及組成物 |
| TW202545974A (zh) | 2024-01-26 | 2025-12-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025194019A1 (fr) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Méthodes de traitement de la fibrose hépatique et de la stéatose hépatique non alcoolique |
| WO2025217275A2 (fr) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Compositions ciblées sur des cellules immunitaires et procédés associés |
| WO2025240680A1 (fr) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Protéines inhibitrices d'immunorécepteurs et procédés associés |
| WO2025245188A2 (fr) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Méthodes de traitement de la stéatose hépatique et d'une stéatose hépatique non alcoolique |
| WO2025245111A1 (fr) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Protéines de ciblage d'immunorécepteurs et procédés associés |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026003582A2 (fr) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipides et nanoparticules lipidiques |
| WO2026055547A1 (fr) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Compositions d'adn et procédés associés |
| WO2026055543A1 (fr) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Compositions d'adn modifiées et procédés associés |
| WO2026064313A1 (fr) | 2024-09-17 | 2026-03-26 | Flagship Pioneering Innovations Vii, Llc | Compositions d'arn et procédés associés |
| WO2026085300A1 (fr) | 2024-10-16 | 2026-04-23 | Flagship Pioneering Innovations Vii, Llc | Procédés et compositions |
| WO2026085495A1 (fr) | 2024-10-18 | 2026-04-23 | Generation Bio Co. | Compositions d'acides nucléiques synthétiques partiellement simples brin, utilisations et procédés associés |
| WO2026096919A1 (fr) | 2024-11-01 | 2026-05-07 | Sail Biomedicines, Inc. | Nouveaux lipides à cœur dipeptidique, vecteurs lipidiques et méthodes d'utilisation de ceux-ci |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) * | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869305A (en) * | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| DE10044384A1 (de) * | 2000-09-08 | 2002-04-18 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| EP1838853A2 (fr) * | 2005-01-06 | 2007-10-03 | Benitec, Inc. | Agents arni pour l'entretien de cellules souches |
| DK2816118T3 (en) * | 2005-05-31 | 2018-12-03 | Univ Colorado Regents | Methods for delivery of genes |
| WO2008016391A2 (fr) * | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Vecteurs parvoviraux auto-complémentaires et leurs procédés de fabrication et d'utilisation |
| AU2016203992A1 (en) * | 2009-05-11 | 2016-06-30 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| EP2500434A1 (fr) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Vecteurs AAV sans capside, compositions et procédés pour la production des vecteurs et la thérapie génique |
| AU2013281328B2 (en) * | 2012-06-27 | 2017-11-23 | MeiraGTx Gene Regulation Limited | Combination for treating an inflammatory disorder |
| US9687448B2 (en) * | 2012-12-07 | 2017-06-27 | Alnylam Pharmaceuticals, Inc. | Nucleic acid lipid particle formulations |
| EP2968586B1 (fr) * | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Composition à base d'arnm du gène cftr et procédés et utilisations associés |
| KR102298579B1 (ko) * | 2013-05-21 | 2021-09-07 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도 |
| WO2015095346A1 (fr) * | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipides et compositions lipidiques destinés à la libération d'agents actifs |
| EP3242945B1 (fr) * | 2015-01-07 | 2021-09-01 | Universitat Autònoma de Barcelona | Construction génique à vecteur unique comprenant des gènes de l'insuline et de la glucokinase |
| US11046955B2 (en) | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| JP7114465B2 (ja) * | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| SG10201913688TA (en) * | 2016-03-03 | 2020-03-30 | Univ Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
-
2018
- 2018-09-07 MX MX2020002501A patent/MX2020002501A/es unknown
- 2018-09-07 IL IL272799A patent/IL272799B2/en unknown
- 2018-09-07 AU AU2018330208A patent/AU2018330208B2/en active Active
- 2018-09-07 CN CN201880057740.5A patent/CN111295448A/zh active Pending
- 2018-09-07 JP JP2020512808A patent/JP2020537493A/ja active Pending
- 2018-09-07 WO PCT/US2018/050042 patent/WO2019051289A1/fr not_active Ceased
- 2018-09-07 EP EP18853914.2A patent/EP3679148A4/fr active Pending
- 2018-09-07 CA CA3075180A patent/CA3075180A1/fr active Pending
- 2018-09-07 KR KR1020207009733A patent/KR102696307B1/ko active Active
- 2018-09-07 BR BR112020004219-6A patent/BR112020004219A2/pt unknown
- 2018-09-07 SG SG11202000765PA patent/SG11202000765PA/en unknown
- 2018-09-07 US US16/644,574 patent/US20210059953A1/en not_active Abandoned
- 2018-09-07 MA MA050096A patent/MA50096A/fr unknown
- 2018-09-07 MY MYPI2020000655A patent/MY209906A/en unknown
-
2020
- 2020-02-28 CO CONC2020/0002262A patent/CO2020002262A2/es unknown
- 2020-03-06 PH PH12020500466A patent/PH12020500466A1/en unknown
-
2022
- 2022-11-02 JP JP2022176366A patent/JP2023002828A/ja active Pending
-
2024
- 2024-10-28 JP JP2024189114A patent/JP2025016593A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020110805A (ru) | 2021-10-11 |
| CA3075180A1 (fr) | 2019-03-14 |
| KR102696307B1 (ko) | 2024-08-16 |
| WO2019051289A1 (fr) | 2019-03-14 |
| IL272799B1 (en) | 2025-07-01 |
| MY209906A (en) | 2025-08-11 |
| US20210059953A1 (en) | 2021-03-04 |
| WO2019051289A9 (fr) | 2019-05-23 |
| KR20200051708A (ko) | 2020-05-13 |
| EP3679148A1 (fr) | 2020-07-15 |
| NZ761412A (en) | 2024-07-05 |
| CN111295448A (zh) | 2020-06-16 |
| AU2018330208B2 (en) | 2025-04-17 |
| JP2025016593A (ja) | 2025-02-04 |
| CO2020002262A2 (es) | 2020-05-29 |
| IL272799B2 (en) | 2025-11-01 |
| MX2020002501A (es) | 2020-09-17 |
| JP2020537493A (ja) | 2020-12-24 |
| IL272799A (en) | 2020-04-30 |
| SG11202000765PA (en) | 2020-03-30 |
| PH12020500466A1 (en) | 2021-01-25 |
| AU2018330208A1 (en) | 2020-02-27 |
| RU2020110805A3 (fr) | 2022-01-19 |
| EP3679148A4 (fr) | 2021-06-09 |
| BR112020004219A2 (pt) | 2020-09-08 |
| JP2023002828A (ja) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272799A (en) | Lipid nanoparticle formulations of non-viral capsid-free DNA vectors | |
| EP3877521A4 (fr) | Formulations de nanoparticules lipidiques | |
| MA49421A (fr) | Formulations d'arn | |
| EP3368089A4 (fr) | Formulations de nanoparticules pour l'administration de complexes d'acide nucléique | |
| IL271389A (en) | Targeted non-viral dna insertions | |
| PT3858333T (pt) | Preparação e armazenamento de formulações de arn lipossómico adequadas para terapia | |
| EP3443092A4 (fr) | Compositions de conjugués d'acides nucléiques ciblés | |
| IL256266A (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| EP3554558A4 (fr) | Conjugués ciblant hsp90 et formulations de ces derniers | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| MA52709A (fr) | Administration d'adn | |
| EP3374494A4 (fr) | Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique | |
| EP3723811A4 (fr) | Conjugués ciblant hsp90 et formulations de ces derniers | |
| MA50354A (fr) | Anticorps ciblant le cd137 et leurs méthodes d'utilisation | |
| HUE055002T2 (hu) | Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra | |
| EP3286321A4 (fr) | Vecteur de virus adéno-associé pour le traitement de l'ataxie de friedreich | |
| EP3518971A4 (fr) | Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations | |
| MA50670A (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
| IL259468A (en) | The reference to formyl peptide receptor 2/lipoxin receptor 4a (fpr2/alx) for the treatment of heart disease | |
| EP3654946A4 (fr) | Formulations en poudre de cromolyne sodique et d'ibuprofène | |
| EP3413909A4 (fr) | Administration sous-cutanée d'adénovirus à double ciblage | |
| EP3394099A4 (fr) | Formulations d'anticorps anti-il-10 modifiés | |
| HUE062806T2 (hu) | Vektorok Friedreich-ataxia kezelésére | |
| EP3442544A4 (fr) | Méthodes améliorées d'administration de gènes | |
| EP3448407A4 (fr) | Protéines dimères pour le ciblage spécifique de séquences d'acides nucléiques |